Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study-Reference-Cited by-同舟云学术

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

Published:2022-10-29 Issue:1 Volume:129 Page:118-129
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Gümüş Mahmut¹^ORCID,Chen Chieh‐I²,Ivanescu Cristina³,Kilickap Saadettin⁴,Bondarenko Igor⁵,Özgüroğlu Mustafa⁶,Gogishvili Miranda⁷,Turk Haci M.⁸,Cicin Irfan⁹,Harnett James²,Mastey Vera²,Naumann Ulrike¹⁰,Reaney Matthew¹⁰,Konidaris Gerasimos¹¹,Sasane Medha¹²,Brady Keri J. S.¹³,Li Siyu²,Gullo Giuseppe²,Rietschel Petra²,Sezer Ahmet¹⁴

Affiliation:

1. Istanbul Medeniyet University, Faculty of Medicine Istanbul Turkey

2. Regeneron Pharmaceuticals, Inc Tarrytown New York USA

3. IQVIA Amsterdam The Netherlands

4. Department of Medical Oncology Istinye University Faculty of Medicine Liv Hospital Ankara Turkey

5. Dnipropetrovsk State Medical Academy City Multifield Clinical Hospital Dnipropetrovsk Ukraine

6. Cerrahpaşa Medical Faculty Istanbul University‐Cerrahpaşa Istanbul Turkey

7. High Technology Medical Centre Tbilisi Georgia

8. Department of Medical Oncology Bezmialem Vakif University Medical Faculty Istanbul Turkey

9. Department of Medical Oncology Trakya University İskender/Edirne Merkez/Edirne Turkey

10. IQVIA Reading UK

11. Sanofi Reading UK

12. Sanofi Bridgewater New Jersey USA

13. Sanofi Cambridge Massachusetts USA

14. Department of Medical Oncology Başkent University Etimesgut Ankara Turkey

Funder

Sanofi

Regeneron Pharmaceuticals

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34477

Reference36 articles.

1. Cancer statistics, 2022

2. American Cancer Society.About lung cancer.https://www.cancer.org/cancer/lung‐cancer/about/what‐is.html. Accessed May 18 2021.

3. Immunotherapy in treatment naïve advanced non-small cell lung cancer

4. Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cemiplimab in treating locally advanced NSCLC;Onkologie;2023-03-01